Noile-Immune Biotech Inc. (TYO:4893)

Noile-Immune Biotech Ratios and Metrics

Market cap in millions JPY. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	6,032	5,759	7,361	9,175	-	-
Market Cap Growth	-21.29%	-21.77%	-19.77%	-	-	-
Enterprise Value	2,289	1,641	2,645	3,519	-	-
Last Close Price	139.00	133.00	170.00	212.00	-	-
PS Ratio	2010.83	1151.83	1051.61	29.03	-	-
PB Ratio	1.60	1.47	1.56	1.61	-	-
P/TBV Ratio	1.60	1.47	1.56	1.61	-	-
EV/Sales Ratio	-	328.23	377.90	11.14	-	-
Net Debt / Equity Ratio	-0.99	-1.00	-0.99	-0.98	-1.05	-0.99
Asset Turnover	0.00	0.00	0.00	0.06	0.14	0.03
Inventory Turnover	14.86	10.40	4.86	3.65	2.00	3.14
Quick Ratio	61.85	53.30	68.58	65.36	13.49	52.41
Current Ratio	62.57	53.82	69.20	66.48	13.68	52.81
Return on Equity (ROE)	-17.09%	-18.32%	-18.52%	-22.63%	-9.10%	-23.44%
Return on Assets (ROA)	-11.25%	-11.31%	-12.63%	-9.31%	-1.49%	-13.79%
Return on Capital Employed (ROCE)	-20.00%	-20.20%	-22.60%	-13.60%	-2.50%	-18.30%
Earnings Yield	-11.70%	-13.77%	-13.10%	-12.32%	-	-
Buyback Yield / Dilution	-	-0.01%	-4.41%	-5.87%	-2.23%	-7.89%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 11, 2026

Data Sources Report a data error